Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 7 | 2026 | 743 | 1.880 |
Why?
|
| Adenocarcinoma | 9 | 2024 | 998 | 1.700 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2026 | 187 | 1.460 |
Why?
|
| Colorectal Neoplasms | 5 | 2025 | 639 | 0.840 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 41 | 0.810 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 75 | 0.790 |
Why?
|
| Antigens, Neoplasm | 1 | 2026 | 402 | 0.780 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 223 | 0.730 |
Why?
|
| Ikaros Transcription Factor | 2 | 2022 | 35 | 0.700 |
Why?
|
| Transaminases | 2 | 2022 | 37 | 0.700 |
Why?
|
| Anemia | 1 | 2024 | 357 | 0.630 |
Why?
|
| Needs Assessment | 2 | 2025 | 175 | 0.590 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 265 | 0.590 |
Why?
|
| Safety-net Providers | 1 | 2020 | 88 | 0.580 |
Why?
|
| Oncologists | 1 | 2019 | 32 | 0.580 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2026 | 950 | 0.560 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 62 | 0.560 |
Why?
|
| Documentation | 1 | 2019 | 119 | 0.550 |
Why?
|
| Exophthalmos | 1 | 2018 | 31 | 0.540 |
Why?
|
| Minority Groups | 1 | 2020 | 258 | 0.540 |
Why?
|
| Bacteremia | 2 | 2021 | 429 | 0.530 |
Why?
|
| Orbital Neoplasms | 1 | 2018 | 49 | 0.520 |
Why?
|
| Orbit | 1 | 2018 | 81 | 0.520 |
Why?
|
| T-Lymphocytes | 1 | 2026 | 1705 | 0.510 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 129 | 0.510 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 127 | 0.510 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 70 | 0.510 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 506 | 0.500 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 406 | 0.500 |
Why?
|
| Rectal Neoplasms | 3 | 2023 | 78 | 0.490 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 90 | 0.480 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 580 | 0.470 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 4 | 0.440 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2014 | 7 | 0.440 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 23 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 573 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1352 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 778 | 0.380 |
Why?
|
| Physicians | 1 | 2019 | 637 | 0.370 |
Why?
|
| Electronic Health Records | 1 | 2019 | 815 | 0.360 |
Why?
|
| Aged | 14 | 2026 | 21286 | 0.350 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2018 | 65 | 0.350 |
Why?
|
| Neoplasms | 2 | 2025 | 2968 | 0.320 |
Why?
|
| Middle Aged | 15 | 2026 | 28944 | 0.320 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 1333 | 0.310 |
Why?
|
| Adult | 17 | 2026 | 31746 | 0.310 |
Why?
|
| Humans | 31 | 2026 | 132038 | 0.270 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1405 | 0.270 |
Why?
|
| Aspergillosis | 2 | 2004 | 46 | 0.270 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 433 | 0.260 |
Why?
|
| Female | 17 | 2026 | 71377 | 0.250 |
Why?
|
| Male | 17 | 2026 | 65421 | 0.250 |
Why?
|
| Paclitaxel | 2 | 2024 | 134 | 0.240 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 703 | 0.240 |
Why?
|
| Anal Canal | 2 | 2023 | 86 | 0.240 |
Why?
|
| Aspergillus | 1 | 2004 | 26 | 0.220 |
Why?
|
| Mannans | 1 | 2004 | 14 | 0.220 |
Why?
|
| Lung Diseases, Fungal | 1 | 2004 | 37 | 0.220 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 155 | 0.210 |
Why?
|
| Albumins | 1 | 2024 | 90 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2025 | 172 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2024 | 307 | 0.190 |
Why?
|
| Communicable Diseases | 1 | 2004 | 158 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1082 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 545 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1490 | 0.170 |
Why?
|
| Blood Culture | 1 | 2021 | 36 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 340 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2025 | 1094 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6930 | 0.160 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 191 | 0.160 |
Why?
|
| Lymph Nodes | 2 | 2019 | 364 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2025 | 563 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 209 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1279 | 0.160 |
Why?
|
| Fraud | 1 | 2019 | 16 | 0.150 |
Why?
|
| Acute Disease | 2 | 2018 | 1153 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 771 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2020 | 77 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 39 | 0.150 |
Why?
|
| Genetic Therapy | 1 | 2024 | 725 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 45 | 0.140 |
Why?
|
| Leucovorin | 3 | 2023 | 54 | 0.140 |
Why?
|
| Mass Screening | 2 | 2015 | 825 | 0.140 |
Why?
|
| Fluorouracil | 3 | 2023 | 134 | 0.140 |
Why?
|
| Physical Examination | 1 | 2019 | 170 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2130 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2026 | 13025 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 322 | 0.140 |
Why?
|
| Gastrectomy | 1 | 2019 | 107 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2015 | 1105 | 0.130 |
Why?
|
| Algorithms | 2 | 2015 | 1690 | 0.130 |
Why?
|
| Myxoma virus | 1 | 2017 | 1 | 0.130 |
Why?
|
| Parvovirus | 1 | 2017 | 7 | 0.130 |
Why?
|
| Orthoreovirus, Mammalian | 1 | 2017 | 7 | 0.130 |
Why?
|
| Measles virus | 1 | 2017 | 16 | 0.130 |
Why?
|
| Vaccinia virus | 1 | 2017 | 50 | 0.130 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 95 | 0.130 |
Why?
|
| Simplexvirus | 1 | 2017 | 100 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 895 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2019 | 399 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2022 | 760 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17747 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 394 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1249 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2014 | 84 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 62 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 506 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2017 | 586 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 147 | 0.100 |
Why?
|
| Microscopy | 1 | 2014 | 121 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2014 | 177 | 0.100 |
Why?
|
| Organ Sparing Treatments | 2 | 2023 | 43 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1140 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2023 | 82 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2015 | 279 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1614 | 0.080 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 120 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1260 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2578 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2023 | 358 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 910 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1621 | 0.060 |
Why?
|
| Foodborne Diseases | 1 | 2004 | 13 | 0.060 |
Why?
|
| Meningococcal Vaccines | 1 | 2005 | 31 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2004 | 15 | 0.050 |
Why?
|
| Galactose | 1 | 2004 | 53 | 0.050 |
Why?
|
| Splenectomy | 1 | 2005 | 63 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 237 | 0.050 |
Why?
|
| Itraconazole | 1 | 2003 | 24 | 0.050 |
Why?
|
| Young Adult | 4 | 2019 | 10128 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 48 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 176 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2023 | 34 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 92 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 631 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2154 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 414 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 279 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 375 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2005 | 389 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 25 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2004 | 285 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 235 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2004 | 326 | 0.040 |
Why?
|
| Psychometrics | 1 | 2025 | 679 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2003 | 298 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 134 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 222 | 0.040 |
Why?
|
| Incidence | 3 | 2017 | 3358 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1601 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2148 | 0.040 |
Why?
|
| Caregivers | 1 | 2025 | 586 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 71 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 88 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 83 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4962 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 120 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 155 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 328 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1522 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 277 | 0.030 |
Why?
|
| Recurrence | 1 | 2022 | 1484 | 0.030 |
Why?
|
| United States | 3 | 2019 | 11846 | 0.030 |
Why?
|
| Rectum | 1 | 2018 | 103 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 440 | 0.030 |
Why?
|
| General Surgery | 1 | 2019 | 222 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 274 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3851 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 1270 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 34260 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5124 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1411 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 4071 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1228 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1609 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3422 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 2118 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2315 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 21018 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3646 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2005 | 25 | 0.010 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 29 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3428 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 796 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 11020 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 683 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3133 | 0.010 |
Why?
|